Adaptive Biotechnologies Corp vs New York Times Co — how do they compare? Adaptive Biotechnologies Corp trades at $24.99 (market cap $4.04B), while New York Times Co trades at $63.84 (market cap $10.28B). The key difference: New York Times Co is far larger — about 2.5× Adaptive Biotechnologies Corp's market cap, and New York Times Co pays a 1.44% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | NYT | |
|---|---|---|
Market Cap | $4.04B | $10.28B |
Sector | Health | Media |
52-Week High | $25.45 | $85.86 |
52-Week Low | $12.30 | $54.66 |
Enterprise Value | $4.10B | $9.67B |
Dividend Yield | — | 1.44% |
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
The New York Times (NYT) stock trades at $64.21, down 0.91% on the day, with a bearish technical signal despite recent earnings beats. Revenue growth remains steady, reaching $2.82 billion in 2025, with net income margins improving to 12.17%. The company faces headwinds from slowing digital subscriber growth, as highlighted in recent quarterly reports, but maintains strong profitability and cash flow generation.
Outlook is mixed; valuation appears full with a P/E of 26.55, yet analyst consensus targets $77.50 suggest upside. Key risks include subscriber growth moderation and competitive pressures. The stock offers a dividend yield with the next payment scheduled for July 23, 2026.
Trailing returns across standard periods
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →